About this trial
Altitude training has been suggested to be of potential support to improve some chronic clinical conditions, especially metabolic conditions. Normobaric hypoxia represents a promising system to simulate altitude training, and its efficacy and safety have been suggested in different conditions, including diabetes, obesity and hypertension. Metabolic dysfunction-associated steatotic liver disease (MASLD) can characterized by metabolic alterations (including altered body composition, lipid and glycemic profile, etc.), and might benefit from aerobic training performed in simulated altitude training (i.e., normobaric hypoxia). Mild altitude training will be proposed (equal to about 2'500 m, 15% FiO2) and compared to a sham normobaric normoxia condition, during an 8-week 3 or 2 times per week 1-h aerobic training (walking) at 60-65% of maximum heart rate (HRmax). Cardiorespiratory fitness, body composition, and metabolic profile will be investigated.
Eligibility criteria
Qualifiers
Being diagnosed with MASLD from at the least 3 years
BMI > 26 kg/m2
Being sedentary
Disqualifiers
Cardiovascular, respiratory, renal complications
Hypertension
COPD
Previous history of acute mountain sickness or altitude-associated symptoms
Trial design
Treatments tested in this trial
- HYPOTRAIN
- NORMOTRAIN